1. Home
  2. DKL vs WVE Comparison

DKL vs WVE Comparison

Compare DKL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKL

Delek Logistics Partners

HOLD

Current Price

$52.49

Market Cap

2.8B

Sector

Energy

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.39

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKL
WVE
Founded
2012
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.4B
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
DKL
WVE
Price
$52.49
$6.39
Analyst Decision
Hold
Strong Buy
Analyst Count
3
16
Target Price
$51.33
$31.19
AVG Volume (30 Days)
57.1K
4.2M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
8.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
$2.04
$0.34
Revenue Next Year
$7.16
$83.30
P/E Ratio
$17.62
N/A
Revenue Growth
N/A
149.43
52 Week Low
$34.59
$5.02
52 Week High
$55.89
$21.73

Technical Indicators

Market Signals
Indicator
DKL
WVE
Relative Strength Index (RSI) 46.15 21.83
Support Level $50.17 N/A
Resistance Level $55.40 $8.15
Average True Range (ATR) 1.57 0.78
MACD -0.10 -0.65
Stochastic Oscillator 35.75 14.23

Price Performance

Historical Comparison
DKL
WVE

About DKL Delek Logistics Partners

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: